Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

HIGHLIGHTS

• who: Filip Gorachinov et al. from the University of SsCyril and Methodius in Skopje, Skopje, North Canada have published the article: Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer, in the Journal: (JOURNAL)
• what: The main reasons behind the limited success of TKI monotherapy in the suppression of lung cancer growth for an extended period are tumor heterogeneity, key signaling pathway alteration, and activation of alternate signaling, which effectively rescue the main inhibited pathway. This approach shows improved clinical outcomes over chemotherapy or MET TKI monotherapy . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.